Nektar Therapeutics Financial Statements (NKTR)
|
|
|
|
Report date
|
|
|
26.02.2021 |
01.03.2022 |
31.12.2022 |
28.02.2023 |
05.03.2024 |
|
08.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
152.9 |
101.9 |
92.1 |
92.1 |
90.1 |
|
93.1 |
|
Operating Income, bln rub |
|
|
-379.9 |
-446.1 |
-376.2 |
-240.2 |
-137.4 |
|
-135.9 |
|
EBITDA, bln rub |
? |
|
-394.3 |
-463.0 |
-325.5 |
-323.9 |
-243.1 |
|
-142.1 |
|
Net profit, bln rub |
? |
|
-444.4 |
-523.8 |
-368.2 |
-368.2 |
-276.1 |
|
-168.3 |
|
|
OCF, bln rub |
? |
|
-313.3 |
-412.7 |
-304.0 |
-304.0 |
-192.6 |
|
-176.6 |
|
CAPEX, bln rub |
? |
|
7.26 |
15.0 |
5.68 |
5.68 |
0.865 |
|
1.25 |
|
FCF, bln rub |
? |
|
-320.5 |
-427.6 |
-309.7 |
-309.7 |
-193.5 |
|
-177.8 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
513.4 |
523.1 |
310.7 |
310.7 |
190.9 |
|
199.0 |
|
Cost of production, bln rub |
|
|
19.5 |
24.9 |
21.6 |
21.6 |
36.6 |
|
30.0 |
|
R&D, bln rub |
|
|
408.7 |
400.3 |
218.3 |
218.3 |
111.3 |
|
122.1 |
|
Interest expenses, bln rub |
|
|
37.1 |
47.3 |
28.9 |
28.9 |
25.3 |
|
24.8 |
|
|
Assets, bln rub |
|
|
1 539 |
1 117 |
710.6 |
710.6 |
398.0 |
|
308.0 |
|
Net Assets, bln rub |
? |
|
1 077 |
679.5 |
366.6 |
366.6 |
131.0 |
|
48.9 |
|
Debt, bln rub |
|
|
150.3 |
143.2 |
131.5 |
131.5 |
230.4 |
|
108.3 |
|
Cash, bln rub |
|
|
1 062 |
734.0 |
505.0 |
505.0 |
303.6 |
|
244.5 |
|
Net debt, bln rub |
|
|
-911.6 |
-590.8 |
-373.5 |
-373.5 |
-73.2 |
|
-136.2 |
|
|
Ordinary share price, rub |
|
|
17.0 |
13.5 |
2.26 |
2.26 |
0.565 |
|
0.490 |
|
Number of ordinary shares, mln |
|
|
178.6 |
183.3 |
187.1 |
187.1 |
190.0 |
|
209.2 |
|
|
Market cap, bln rub |
|
|
3 036 |
2 476 |
423 |
423 |
107 |
|
103 |
|
EV, bln rub |
? |
|
2 124 |
1 886 |
49 |
49 |
34 |
|
-34 |
|
Book value, bln rub |
|
|
1 001 |
603 |
290 |
290 |
131 |
|
49 |
|
|
EPS, rub |
? |
|
-2.49 |
-2.86 |
-1.97 |
-1.97 |
-1.45 |
|
-0.80 |
|
FCF/share, rub |
|
|
-1.79 |
-2.33 |
-1.65 |
-1.65 |
-1.02 |
|
-0.85 |
|
BV/share, rub |
|
|
5.60 |
3.29 |
1.55 |
1.55 |
0.69 |
|
0.23 |
|
|
EBITDA margin, % |
? |
|
-257.9% |
-454.3% |
-353.6% |
-351.8% |
-269.8% |
|
-152.6% |
|
Net margin, % |
? |
|
-290.6% |
-514.0% |
-400.0% |
-400.0% |
-306.3% |
|
-180.7% |
|
FCF yield, % |
? |
|
-10.6% |
-17.3% |
-73.2% |
-73.2% |
-180.2% |
|
-173.4% |
|
ROE, % |
? |
|
-41.3% |
-77.1% |
-100.4% |
-100.4% |
-210.8% |
|
-344.3% |
|
ROA, % |
? |
|
-28.9% |
-46.9% |
-51.8% |
-51.8% |
-69.4% |
|
-54.6% |
|
|
P/E |
? |
|
-6.83 |
-4.73 |
-1.15 |
-1.15 |
-0.39 |
|
-0.61 |
|
P/FCF |
|
|
-9.47 |
-5.79 |
-1.37 |
-1.37 |
-0.55 |
|
-0.58 |
|
P/S |
? |
|
19.9 |
24.3 |
4.59 |
4.59 |
1.19 |
|
1.10 |
|
P/BV |
? |
|
3.03 |
4.11 |
1.46 |
1.46 |
0.82 |
|
2.10 |
|
EV/EBITDA |
? |
|
-5.39 |
-4.07 |
-0.15 |
-0.15 |
-0.14 |
|
0.24 |
|
Debt/EBITDA |
|
|
2.31 |
1.28 |
1.15 |
1.15 |
0.30 |
|
0.96 |
|
|
R&D/CAPEX, % |
|
|
5 631% |
2 670% |
3 846% |
3 846% |
12 865% |
|
9 800% |
|
|
CAPEX/Revenue, % |
|
|
4.75% |
14.7% |
6.17% |
6.17% |
0.96% |
|
1.34% |
|
| Nektar Therapeutics shareholders |
